Why Manitowoc, Endocyte, and Seattle Genetics Tumbled Today

Stocks generally disappointed investors on Friday as the Ukrainian situation trumped strong jobs data, but these three stocks performed much worse than the broader market. Find out why.

May 2, 2014 at 8:35PM

Stocks closed modestly lower Friday, as violence in Ukraine's third-largest city raised the chances of more aggressive Russian intervention and whatever response Western nations would make to such a move. Favorable jobs data helped counteract the impact of geopolitical tension somewhat, but Manitowoc (NYSE:MTW), Endocyte (NASDAQ:ECYT), and Seattle Genetics (NASDAQ:SGEN) all fell much more sharply than the broader stock market, as troubling news affected their respective businesses.

Manitowoc fell 10% after the company reported surprising weakness in its crane-manufacturing segment. Although Manitowoc saw adjusted earnings jump 62% from the year-ago quarter, revenue fell 5%, with an even greater 14% drop in crane sales offsetting strength in Manitowoc's foodservice equipment division. Investors weren't satisfied with Manitowoc's reiteration of its full-year guidance, even though it implies that the company expects to make up for any shortfall during the remainder of the year. With other construction-equipment companies reporting more favorable results, investors will have to decide whether Manitowoc's results are a one-time aberration or a sign that its rivals are doing a better job of capturing opportunities in the recovering construction market.

Source: Manitowoc.

Endocyte plunged 62% after the company announced a setback for its vintafolide treatment. Endocyte had received a positive opinion for condition marketing authorization for the drug by the European Committee for Medicinal Products for Human Use earlier this year, raising hopes for the company's future. But a data safety monitoring board covering a phase 3 trial of Endocyte's vintafolide in the U.S. recommended that the trial be stopped because it hadn't met its goal of greater progression-free survival for platinum-resistant ovarian-cancer patients. With the bad news, Endocyte will have to work with its partner to determine whether to keep developing vintafolide, or concentrate on other opportunities.

Seattle Genetics dropped 11% even as the biotech announced solid revenue growth in its first-quarter results last night. Sales for Seattle Genetics rose 19%, with just about all of its revenue coming from product sales and affiliated revenue related to its Adcetris antibody-drug conjugate, which has thus far received FDA approval to treat Hodgkin's lymphoma and anaplastic large-cell lymphoma. Yet, even those results weren't enough to satisfy Seattle Genetics shareholders, and guidance for the full year suggested that Adcetris' upside could be far more limited than investors previously thought. Although the technology behind antibody-drug conjugates has great potential, Seattle Genetics will need to capitalize on that potential in order to reassure shareholders.

You don't want to miss this
The Economist compares this disruptive invention to the steam engine and the printing press. Business Insider says it's "the next trillion dollar industry." And everyone from BMW, to shoemakers, to the U.S. Air Force is already using it every day. Watch The Motley Fool's shocking video presentation today to discover the garage gadget that's putting an end to the Made In China era... and learn the investing strategy we've used to double our money on these three stocks. Click here to watch now!

Dan Caplinger has no position in any stocks mentioned. The Motley Fool recommends Seattle Genetics. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information